Qsemble Capital Management LP Has $2.86 Million Stake in IQVIA Holdings Inc. (NYSE:IQV)

Qsemble Capital Management LP lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 169.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,061 shares of the medical research company's stock after purchasing an additional 7,580 shares during the quarter. Qsemble Capital Management LP's holdings in IQVIA were worth $2,858,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of IQV. Versant Capital Management Inc grew its stake in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company's stock valued at $26,000 after buying an additional 110 shares during the last quarter. Opal Wealth Advisors LLC acquired a new position in IQVIA in the 2nd quarter valued at $27,000. Capital Performance Advisors LLP acquired a new stake in IQVIA in the 3rd quarter worth $27,000. Park Place Capital Corp acquired a new stake in IQVIA in the 3rd quarter worth $28,000. Finally, Itau Unibanco Holding S.A. acquired a new stake in IQVIA in the 2nd quarter worth $29,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have issued reports on IQV. JPMorgan Chase & Co. decreased their price target on shares of IQVIA from $279.00 to $240.00 and set an "overweight" rating on the stock in a research report on Tuesday, November 5th. The Goldman Sachs Group decreased their target price on shares of IQVIA from $280.00 to $250.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. StockNews.com upgraded shares of IQVIA from a "hold" rating to a "buy" rating in a research report on Wednesday, November 20th. TD Cowen decreased their target price on shares of IQVIA from $270.00 to $255.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Finally, Truist Financial decreased their target price on shares of IQVIA from $286.00 to $265.00 and set a "buy" rating on the stock in a research report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, IQVIA currently has a consensus rating of "Moderate Buy" and a consensus price target of $256.50.

IQVIA Price Performance

NYSE:IQV traded down $2.78 on Tuesday, reaching $201.24. The stock had a trading volume of 1,370,041 shares, compared to its average volume of 1,178,988. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73. The stock has a fifty day moving average price of $221.18 and a 200-day moving average price of $226.75. The company has a market capitalization of $36.53 billion, a P/E ratio of 26.41, a price-to-earnings-growth ratio of 2.08 and a beta of 1.51. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.